Andrew Singer
Directeur/Membre du Conseil chez ENLIVEX THERAPEUTICS LTD.
Profil
Mr. Andrew E.
Singer is an Independent Director at Enlivex Therapeutics Ltd.
He is on the Board of Directors at Enlivex Therapeutics Ltd.
and J.F.
Kapnek Trust.
Mr. Singer was previously employed as a CFO, Treasurer & EVP-Finance & Administration by Epizyme, Inc., a Head-Health Care Investment Banking Group by RBC Capital Markets Corp., and a Co-Founder by MVC Capital, Inc. He received his undergraduate degree from Yale University and an MBA from Harvard Business School.
Postes actifs de Andrew Singer
| Sociétés | Poste | Début |
|---|---|---|
| ENLIVEX THERAPEUTICS LTD. | Directeur/Membre du Conseil | 17/04/2023 |
| J.F. Kapnek Trust | Directeur/Membre du Conseil | - |
Anciens postes connus de Andrew Singer
| Sociétés | Poste | Fin |
|---|---|---|
| EPIZYME, INC. | Directeur Financier/CFO | 31/08/2017 |
| RBC Capital Markets Corp. | Corporate Officer/Principal | 01/01/2015 |
| MVC CAPITAL, INC. | Fondateur | - |
Formation de Andrew Singer
| Yale University | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ENLIVEX THERAPEUTICS LTD. | Health Technology |
| Entreprise privées | 4 |
|---|---|
MVC Capital, Inc.
 MVC Capital, Inc. Investment ManagersFinance MVC Capital, Inc is private Equity fund invest in equity and debt investment capital to fund growth, acquisitions, and recapitalizations of small and middle-market companies located in the United States. company operates through the MVC and MVCFS segments. The MVC segment consists of MVC Cayman and MVC Turf. The MVCFS segment refers to its subsidiary which provides advisory, administrative, and other services to the company and its portfolio companies. It participates in senior and subordinated loans, common and preferred stock, and warrants or rights to acquire equity interests, or convertible securities requirements. | Finance |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
| RBC Capital Markets Corp. | Finance |
| J.F. Kapnek Trust |